Skip to content
10-Q/A

Quarterly Report

Twist Bioscience Corporation TWST

0001581280-26-000029

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Jan 27, 2026 61.31M sh
Shares Diluted Q1 2026 · Dec 31, 2025 61.08M sh
Shares Diluted Q1 2026 · Dec 31, 2024 59.16M sh
Capex Q1 2026 · Dec 31, 2025 $9.97M
Capex Q1 2026 · Dec 31, 2024 $2.27M
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$24.81M
Operating Cash Flow Q1 2026 · Dec 31, 2024 −$21.43M
Short Term Investments Q1 2026 · Dec 31, 2025 $49.36M
Short Term Investments Q1 2026 · Sep 30, 2025 $49.39M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $148.59M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $183.05M
Stockholders Equity Q1 2026 · Dec 31, 2025 $456.1M
Stockholders Equity Q1 2026 · Sep 30, 2025 $472.96M
Stockholders Equity Q1 2026 · Dec 31, 2024 $455.94M
Stockholders Equity Q1 2026 · Sep 30, 2024 $472.69M
Current Liabilities Q1 2026 · Dec 31, 2025 $80.44M
Current Liabilities Q1 2026 · Sep 30, 2025 $91.41M
Total Liabilities Q1 2026 · Dec 31, 2025 $181.99M
Total Liabilities Q1 2026 · Sep 30, 2025 $168.9M
Current Assets Q1 2026 · Dec 31, 2025 $303.88M
Current Assets Q1 2026 · Sep 30, 2025 $332.97M
Total Assets Q1 2026 · Dec 31, 2025 $638.09M
Total Assets Q1 2026 · Sep 30, 2025 $641.86M
Eps Diluted Q1 2026 · Dec 31, 2025 −$0.50
Eps Diluted Q1 2026 · Dec 31, 2024 −$0.53
Eps Basic Q1 2026 · Dec 31, 2025 −$0.50
Eps Basic Q1 2026 · Dec 31, 2024 −$0.53
Sga Expense Q1 2026 · Dec 31, 2025 $69.74M
Sga Expense Q1 2026 · Dec 31, 2024 $56.18M
Rd Expense Q1 2026 · Dec 31, 2025 $17.13M
Rd Expense Q1 2026 · Dec 31, 2024 $21.31M
Net Income Q1 2026 · Dec 31, 2025 −$30.51M
Net Income Q1 2026 · Dec 31, 2024 −$31.59M
Operating Income Q1 2026 · Dec 31, 2025 −$32.9M
Operating Income Q1 2026 · Dec 31, 2024 −$34.64M
Cost Of Revenue Q1 2026 · Dec 31, 2025 $49.73M
Cost Of Revenue Q1 2026 · Dec 31, 2024 $45.87M
Revenue Q1 2026 · Dec 31, 2025 $103.7M
Revenue Q1 2026 · Dec 31, 2024 $88.71M